Rapamycin (Sirolimus) Microdosing Protocols: What the Evidence Actually Shows

What Is Rapamycin and Why Is It Being Microdosed?

Rapamycin (generic name sirolimus) was isolated from the soil bacterium Streptomyces hygroscopicus on Easter Island in 1972 and FDA-approved in 1999 for prevention of renal-transplant rejection [1]. Its mechanism, inhibition of mechanistic target of rapamycin complex 1 (mTORC1), overlaps with one of the most studied aging pathways in model organisms. The drug extended median lifespan in genetically heterogeneous mice by 9 to 14% even when started at 600 days of age, equivalent to roughly 60 human years [2].

That mouse data sparked off-label prescribing in healthy older adults. The central hypothesis: brief, periodic mTORC1 inhibition may mimic the cellular quality-control processes that caloric restriction activates, without the practical difficulty of sustained caloric restriction.

Why "Microdosing" Rather Than Full Transplant Doses

Transplant-rejection protocols run at 2 to 5 mg per day continuously, targeting trough blood levels of 4 to 12 ng/mL. At those doses, meaningful immunosuppression, hyperlipidemia, impaired wound healing, and mouth sores are common enough to be listed as boxed-warning concerns by the FDA [1].

Longevity prescribers drop the dose to 1 to 6 mg once weekly (occasionally biweekly), aiming for trough levels well below 3 ng/mL. The logic is pharmacokinetic: sirolimus has an approximately 62-hour half-life [3], so a once-weekly pulse allows near-complete drug clearance before the next dose. Intermittent dosing may preserve immune competence while still achieving transient mTORC1 inhibition in peripheral blood mononuclear cells.

How mTORC1 Inhibition Connects to Aging Biology

MTORC1 sits upstream of S6 kinase 1 (S6K1) and 4E-BP1, two translation regulators that increase protein synthesis and suppress autophagy. Chronic mTORC1 hyperactivity correlates with cellular senescence accumulation, mitochondrial dysfunction, and inflammaging [4]. Periodic inhibition restores autophagy flux, which clears damaged organelles and misfolded proteins. Whether this translates to meaningful human longevity benefit remains an open clinical question.

The PEARL Trial: The Best Human Evidence So Far

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) published in Aging Cell in 2024 is the highest-quality prospective human trial of low-dose sirolimus in healthy older adults to date [5].

Study Design and Population

PEARL enrolled 114 community-dwelling adults aged 50 to 85 with no active malignancy, organ transplant, or uncontrolled diabetes. Participants were randomized to one of three arms: placebo, sirolimus 5 mg once weekly, or sirolimus 10 mg every two weeks. The primary endpoint was change in a validated self-reported health score (PROMIS Global Health) over 8 weeks of treatment.

Key Findings

The 5 mg weekly arm showed a statistically significant improvement in PROMIS Global Health physical score compared with placebo (P<0.05) at week 8 [5]. The 10 mg biweekly arm did not reach significance on the same measure. Neither active arm produced a significant increase in serious adverse events versus placebo over the study window.

Secondary immune analyses found that the 5 mg weekly group had a modest reduction in a subset of exhausted CD8+ T cells, a marker associated with immune aging. The authors described this as "preliminary evidence that short-term, low-dose rapamycin may improve immune function in aging adults" [5].

What PEARL Does Not Tell Us

Eight weeks is a short observation window for an aging intervention. PEARL was not powered to assess mortality, cancer incidence, cardiovascular events, or functional independence. Lipid panels and fasting glucose were tracked but the trial was not designed to detect long-term metabolic effects. Larger and longer trials are required before drawing conclusions about net clinical benefit.

Earlier Supporting Evidence: The Mannick Studies

Before PEARL, Joan Mannick and colleagues published two landmark studies using everolimus (a sirolimus analog) in older adults that laid the scientific groundwork for the microdosing hypothesis.

Mannick 2014 (Science Translational Medicine)

In a double-blind RCT of 218 adults aged 65 or older, six weeks of low-dose RAD001 (everolimus) at 0.5 mg daily or 5 mg weekly improved influenza vaccine response by approximately 20% compared with placebo (P<0.001) [6]. This remains the most cited human evidence that intermittent mTOR inhibition can improve immune function in older adults rather than suppressing it.

Mannick 2018 (Science Translational Medicine)

A follow-up trial of 264 older adults tested three everolimus doses for 16 weeks and again found that the two lower-dose arms (0.1 mg daily or 1 mg weekly) reduced self-reported infection frequency over the subsequent year by approximately 25% compared with placebo (P<0.05) [7]. The highest dose (5 mg weekly) did not clearly outperform the lower doses, suggesting a non-linear dose-response relationship.

Current Microdosing Protocols in Clinical Practice

No FDA-approved protocol exists for longevity use. The regimens below reflect published research arms and the range used by longevity-focused physicians, not official prescribing guidance.

The Once-Weekly 1 to 6 mg Protocol

The most commonly described protocol in the published literature and in clinical longevity practices is oral sirolimus 1 to 6 mg taken once weekly, fasted or with a low-fat meal (high-fat meals increase sirolimus bioavailability by roughly 35% [3], which some practitioners exploit to lower the nominal milligram dose).

A reasonable titration approach used by some longevity physicians:

• Weeks 1 to 4: 1 mg once weekly, check trough level at week 4
• Weeks 5 to 8: 2 to 3 mg once weekly if trough is <3 ng/mL and no adverse effects
• Weeks 9 onward: 4 to 6 mg once weekly if tolerability is confirmed and trough remains <3 to 5 ng/mL

Trough blood levels should be drawn 7 days after the most recent dose (i.e., immediately before the next scheduled dose) to reflect nadir rather than peak exposure.

The Biweekly 5 to 10 mg Protocol

Some practitioners prefer 5 to 10 mg every two weeks, mirroring PEARL's 10 mg biweekly arm and Mannick's 5 mg weekly everolimus arm. The longer washout period may lower average systemic exposure further. PEARL did not find a statistically significant benefit on the primary endpoint in this arm, but the biweekly format is still explored in ongoing trials.

Cyclical "On/Off" Schedules

A third approach uses 6 to 12 weeks of weekly dosing followed by a 4 to 8 week drug holiday. The rationale: prolonged continuous mTORC1 inhibition may eventually relieve negative-feedback inhibition of mTORC2, potentially worsening insulin signaling [4]. Cycling is theoretically protective against that rebound, though no published RCT has directly compared cycling versus continuous weekly dosing in humans.

Pharmacokinetics Relevant to Microdosing

Sirolimus is a substrate of CYP3A4 and P-glycoprotein. At oral doses of 1 to 6 mg, peak plasma concentration (Cmax) occurs at approximately 1 to 2 hours post-dose, and the mean half-life is 62 hours (standard deviation roughly 16 hours in healthy adults) [3]. By day 7, a 5 mg single dose would be expected to produce residual concentrations of roughly 0.3 to 0.8 ng/mL in most adults, well below the 4 ng/mL threshold associated with transplant-level immunosuppression.

Drug Interactions That Matter

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) can increase sirolimus AUC by 4 to 11 fold [3]. Strong inducers like rifampin reduce exposure by up to 82%. Any patient adding or removing a strong CYP3A4 modifier mid-protocol needs repeat trough monitoring.

Effect of Food on Absorption

A high-fat meal (900 kcal, 54 g fat) increased sirolimus Cmax by 34% and AUC by 35% versus fasting in the FDA label pharmacokinetic data [3]. Practitioners who instruct patients to take their dose with consistent meal conditions reduce intra-patient variability. Most longevity protocols standardize to fasted or low-fat meal conditions.

Safety Profile at Microdose Ranges

The safety signals seen at transplant doses are dose-dependent, and the limited human longevity data suggest a meaningfully better tolerability profile at microdose ranges. The observation periods in every longevity trial to date have been short (8 to 16 weeks), and long-term safety data simply do not exist yet.

Adverse Effects Reported in Longevity Trials

In PEARL, the most common adverse events in the active arms were:

• Mouth sores or oral ulcers (approximately 20% in the 5 mg weekly arm vs. 5% placebo)
• Mild transient headache
• Mild acne or skin changes

No serious infections, serious thromboembolic events, or grade 3 to 4 laboratory abnormalities were reported at significantly higher rates than placebo in PEARL's 8-week window [5].

Lipid Effects

Sirolimus is known to raise triglycerides and LDL cholesterol at transplant doses. The Mannick everolimus trials reported minimal lipid changes at low-dose intermittent regimens [6, 7]. Clinicians monitoring longevity patients should obtain a fasting lipid panel at baseline and at approximately 3 months.

Wound Healing and Surgery

The FDA boxed warning for sirolimus specifically addresses impaired wound healing [1]. Patients on any sirolimus protocol should stop the drug at least 2 weeks before elective surgery. This applies even at microdoses given the drug's long half-life.

Immunosuppression Risk

A single 5 mg weekly dose produces trough levels far below those causing clinically significant immunosuppression in transplant medicine. Still, patients with active infections should hold the drug. Baseline CBC with differential and repeat monitoring every 3 to 6 months is standard in most published longevity protocols.

Who Is (and Is Not) a Candidate for Off-Label Sirolimus

Off-label prescribing of sirolimus for longevity is legal in the United States when a licensed physician determines it is in a patient's best interest, but it sits outside any FDA-approved indication [1]. The following categories reflect clinical practice considerations, not formal guideline recommendations, because no major society has issued longevity-specific sirolimus guidelines as of early 2025.

Reasonable Candidate Profile

Adults generally considered by longevity physicians for this protocol include those who are:

• 50 years of age or older, with no active malignancy
• Free of organ transplant or current immunosuppressive therapy
• Without uncontrolled diabetes (sirolimus may worsen insulin resistance at higher doses)
• Able to commit to baseline and monitoring labs
• Not pregnant or planning pregnancy (sirolimus is Pregnancy Category C)

Contraindications and Cautions

The drug should be avoided or used with extreme caution in patients with:

• Known hypersensitivity to sirolimus or any excipient in the formulation
• Active serious infection
• Hepatic impairment (Child-Pugh B or C), which significantly prolongs half-life
• Concurrent strong CYP3A4 inhibitors that cannot be discontinued
• BMI <18.5 or significant malnutrition, given autophagy pathway interactions

Monitoring Protocol Recommended in Published Literature

A practical monitoring framework synthesized from PEARL [5] and transplant pharmacokinetic literature [3]:

Before starting:

• Comprehensive metabolic panel (CMP)
• Complete blood count with differential
• Fasting lipid panel
• Fasting glucose and HbA1c
• Sirolimus trough level (should be undetectable at baseline)
• Review of all CYP3A4-interacting medications

At 4 weeks:

• Sirolimus trough level (drawn day 7 post-dose)
• Brief symptom review (oral ulcers, skin changes, headache)

At 3 months:

• Fasting lipid panel
• CMP
• CBC
• Sirolimus trough level

Every 6 months thereafter:

• All of the above
• Blood pressure (mTOR inhibitors have mild vasoconstrictive effects at transplant doses)

Where the Research Is Heading

The Targeting Aging with Rapamycin (TAME-like) and AgingOS registries are collecting observational data from individuals already taking off-label sirolimus. The PEARL investigators announced plans for a longer follow-up extension. Several groups are studying whether co-administration of metformin or acarbose provides additive mTOR-pathway benefit. None of these efforts has yet produced phase 3 outcome data.

The American Federation for Aging Research (AFAR) noted in 2023 commentary that "rapamycin is the most promising drug for translation from animal longevity studies to humans" while emphasizing that no human longevity trial has reported a hard clinical endpoint such as reduced mortality or reduced incident disease [8].